Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer and Transtech Pharma have entered into a license agreement for the development and commercialization of compounds that could be used in the treatment of Alzheimer's disease.
Subscribe to our email newsletter
Pfizer will receive exclusive worldwide rights to commercialize TransTech's portfolio of compounds, while TransTech will receive upfront and milestone payments of $155 million with the potential for more. TransTech will also receive royalties on worldwide sales of products.
The compounds currently undergoing trials target the receptor for advanced glycation end products, which is associated with several diseases.
TransTech Pharma is a majority-owned affiliate of MacAndrews & Forbes Holdings.